In January, Marina Litvin, MD, an Associate Professor of Medicine at WashU Medicine’s Division of Endocrinology, Metabolism and Lipid Research, published an editorial titled “Metabolic Syndrome in the Post-ETI Era” in the Journal of Cystic Fibrosis.
Cystic fibrosis (CF) is an autosomal recessive disease caused by defective cystic fibrosis transmembrane regulator channels which leads to lung disease, bronchiectasis, chronic sinus cystitis, absence of the vas deferens, pancreatic insufficiency, cystic fibrosis-related diabetes (CFRD), osteoporosis and malnutrition.
In her thought-provoking editorial, Dr. Litvin details how advancements in modulator therapy have resulted in the improvement of lung function, nutritional status and longevity in patients with CF. Furthermore, due to associated weight gain and rising rates of metabolic syndrome and cardiovascular risks, Dr. Litvin emphasizes that GLP-1/GIP receptor agonist therapy “presents an exciting treatment option that deserves a bigger spotlight and more prospective studies in people with CF, as it will likely become the standard of care when treating overnutrition, obesity and some forms of CFRD.”
Marina Litvin, Metabolic syndrome in the post-ETI era, Journal of Cystic Fibrosis, Volume 24, Issue 1, 2025, Pages 8-9, ISSN 1569-1993, https://doi.org/10.1016/j.jcf.2024.12.008